Payment overview · 2025
General Payments
$329.26
18 reported records · 13 companies
Healthcare provider profile · identity verified
Jeffrey A Potts, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAY CITY, MI · NPI 1700804820
Verified facts
What the public records show
CMS Open Payments records show Jeffrey A Potts, MD received $329.26 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.38 | 20.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.45 | 12.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.28 | 11.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.25 | 9.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.65 | 7.2% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $17.66 | 5.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.03 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.62 | 5.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.29 | 4.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.22 | 4.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.18 | 4.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.02 | 4.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.23 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.26 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.74 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.25 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 272 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 239 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 97 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 57 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
68 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
272 | 268 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1096 | 317 |
| Amlodipine Besylate | Amlodipine Besylate | 753 | 223 |
| Lisinopril | Lisinopril | 648 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 589 | 162 |
| Simvastatin | Simvastatin | 589 | 168 |
| Losartan Potassium | Losartan Potassium | 586 | 168 |
| Metformin Hcl | Metformin Hcl | 581 | 176 |
| Omeprazole | Omeprazole | 404 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 106 |
| Furosemide | Furosemide | 308 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 298 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 294 | 97 |
| Allopurinol | Allopurinol | 273 | 72 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 272 | 268 |
| Metoprolol Tartrate | Metoprolol Tartrate | 262 | 77 |
| Prednisone | Prednisone | 256 | 198 |
| Hydrochlorothiazide | Hydrochlorothiazide | 242 | 66 |
| Eliquis | Apixaban | 239 | 57 |
| Potassium Chloride | Potassium Chloride | 238 | 80 |
| Atenolol | Atenolol | 235 | 68 |
| Glimepiride | Glimepiride | 216 | 67 |
| Pioglitazone Hcl | Pioglitazone Hcl | 213 | 61 |
| Celecoxib | Celecoxib | 212 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 209 | 59 |
| Sertraline Hcl | Sertraline Hcl | 202 | 58 |
| Trazodone Hcl | Trazodone Hcl | 199 | 71 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 195 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 57 |
| Famotidine | Famotidine | 166 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 165 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 51 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 159 | 159 |
| Gabapentin | Gabapentin | 134 | 51 |
| Carvedilol | Carvedilol | 133 | 33 |
| Ozempic | Semaglutide | 132 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 51 |
| Meloxicam | Meloxicam | 125 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 34 |
| Jardiance | Empagliflozin | 111 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 24 |
| Warfarin Sodium | Warfarin Sodium | 98 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 30 |
| Mounjaro | Tirzepatide | 97 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 25 |
| Glipizide | Glipizide | 94 | 25 |
| Bupropion Xl | Bupropion Hcl | 93 | 31 |
| Donepezil Hcl | Donepezil Hcl | 93 | 23 |
| Tramadol Hcl | Tramadol Hcl | 93 | 35 |
| Ezetimibe | Ezetimibe | 92 | 28 |
| Amoxicillin | Amoxicillin | 91 | 73 |
| Finasteride | Finasteride | 90 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 26 |
| Montelukast Sodium | Montelukast Sodium | 85 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 78 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 27 |
| Spironolactone | Spironolactone | 73 | 23 |
| Baclofen | Baclofen | 71 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 22 |
| Alendronate Sodium | Alendronate Sodium | 68 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 36 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 68 | 62 |
| Xarelto | Rivaroxaban | 68 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 46 |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 64 | 23 |
| Topiramate | Topiramate | 63 | 19 |
| Alprazolam | Alprazolam | 61 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 19 |
| Lovastatin | Lovastatin | 60 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 47 |
| Farxiga | Dapagliflozin Propanediol | 51 | 16 |
| Ibuprofen | Ibuprofen | 49 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 12 |
| Betamethasone Valerate | Betamethasone Valerate | 46 | 38 |
| Buspirone Hcl | Buspirone Hcl | 46 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 12 |
| Cephalexin | Cephalexin | 43 | 31 |
| Metolazone | Metolazone | 43 | 18 |
| Enalapril Maleate | Enalapril Maleate | 42 | 13 |
| Benazepril Hcl | Benazepril Hcl | 41 | 11 |
| Trulicity | Dulaglutide | 40 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 39 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Nystatin | Nystatin | 37 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 23 |
| Naproxen | Naproxen | 35 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 15 |
| Ondansetron Odt | Ondansetron | 34 | 22 |
| Propranolol Hcl | Propranolol Hcl | 34 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 12 |
| Meclizine Hcl | Meclizine Hcl | 30 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 24 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Diazepam | Diazepam | 27 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 20 |
| Bumetanide | Bumetanide | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Lorazepam | Lorazepam | 19 | suppressed |
| Nadolol | Nadolol | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | 13 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | 11 |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 12 |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.26 · 18 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, MOUNJARO, NEFFY, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Veozah, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error